GSK is expanding its oncology drug pipeline through acquisitions and promising clinical trial results, including a 94% response rate for its lung cancer drug Jideytro. The company plans to save nearly £1.90 billion in costs, reinvesting these funds to accelerate drug development and offset patent expirations. Analysts see nearly 20% upside potential, reflecting confidence in GSK's strategic growth and innovation efforts.
As of Sep 15, 2026 20:48 WIB, GSK shares are trading at USD 49.65 on Pluang, down 0.80% for the day. The company holds a market capitalization of $100.50 billion and offers a dividend yield of 3.63%. This pricing context highlights investor response amid GSK's focus on oncology growth and cost savings strategies.
GSK's hepatitis B treatment, Hibsago (bepirovirsen), received FDA approval for adults with chronic hepatitis B without cirrhosis, supporting Jefferies' forecast of peak annual sales at £2.2 billion. The drug offers a potential functional cure, allowi...
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
